Louveau, Baptiste
Jouenne, Fanélie
Têtu, Pauline
Sadoux, Aurélie
Gruber, Aurélia
Lopes, Eddie
Delyon, Julie
Serror, Kevin
Marco, Oren
Da Meda, Laetitia
Ndiaye, Aminata
Lermine, Alban
Dumaz, Nicolas
Battistella, Maxime
Baroudjian, Barouyr
Lebbe, Céleste
Mourah, Samia
Article History
First Online: 5 November 2020
Declarations
:
: No external funding was used in the preparation of this article.
: Barouyr Baroudjian declares honoraria from BMS, MSD, Novartis, and Pierre Fabre and travel accommodations from BMS and Pierre Fabre. Maxime Battistella declares a consulting role for Innate Pharma and Kyowa Kirin, honoraria from BMS and Takeda, travel accommodations from Roche, and research funding from Takeda and Kyowa Kirin. Julie Delyon declares travel accommodations from Pierre Fabre and Roche. Céleste Lebbe declares a consulting role for Amgen, BMS, MSD, Novartis, and Roche, research funding from BMS and Roche, honoraria from Amgen, BMS, Incyte, MSD, Novartis, Pfizer, Pierre Fabre, and Roche, and travel accommodations from BMS. Samia Mourah declares a consulting role for Novartis, Biocartis, and Roche and research funding from Roche, Novartis, BMS, and Biocartis. Laetitia Da Meda, Nicolas Dumaz, Aurélia Gruber, Fanélie Jouenne, Alban Lermine, Eddie Lopes, Baptiste Louveau, Oren Marco, Aminata Ndiaye, Aurélie Sadoux, Kevin Serror, and Pauline Têtu have no conflicts of interest that are directly relevant to the content of this article.
: The INSERM Research Ethics Committee has confirmed that no ethical approval is legally required for this retrospective study.
: Informed consent was obtained from all individual participants included in the study.
: Sequencing data analyzed in this study have been deposited in the NCBI Sequence Read Archive (SRA). The accession number is PRJNA647798.
: Not applicable.
: Conceptualization: SM, CL. Data curation: BL, FJ, AS, AG, EL, AN, AL. Formal analysis: BL, FJ. Investigation: BL, FJ, PT, AS, AG, EL, MB. Methodology: BL, FJ. Project administration: CL, SM. Resources: PT, JD, KS, OM, LDM, MB, BB. Software: AN, AL. Supervision: CL, SM. Validation: BL, FJ, CL, SM. Visualization: BL, FJ. Writing original draft: BL, FJ. Writing review and editing: ND, CL, SM.